Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 25, 2023Scientific ReportsOpen Access

Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHaifeng LvYJYanming JiangGZGeli Zhu

Discussion

Loading...

Member takes

Overview

Case-control study reveals higher liver fibrosis risk linked to metabolic conditions in co-infected individuals, highlighting non-viral clinical targets.

Key Points

  • To identify clinical characteristics and evaluate risk factors for liver fibrosis in patients with metabolic associated fatty liver disease (MAFLD) co-infected with hepatitis B virus (HBV).
  • Retrospective case-control analysis of 401 biopsy-proven MAFLD patients categorized into MAFLD with HBV (n = 179) and MAFLD alone.
  • Propensity score matching (PSM) generated 83 balanced pairs to compare histological characteristics between cohorts.
  • Multivariate logistic regression identified independent risk factors associated with significant liver fibrosis.
  • In propensity-matched pairs, the MAFLD + HBV cohort displayed lower steatosis scores and ballooning but higher inflammation scores and liver fibrosis stages compared to MAFLD controls.
  • HBV co-infection independently correlated with increased odds of significant liver fibrosis in MAFLD (adjusted OR: 3.140, P = 0.003), with 43.58% (78/179) of MAFLD + HBV patients presenting with significant fibrosis.
  • Within the MAFLD + HBV group, significant fibrosis risk was driven by metabolic indicators: hypertension (OR: 2.640, P = 0.031), type 2 diabetes (OR: 4.939, P = 0.035), and elevated glutamyl-transferase (OR: 3.980, P = 0.001).

Cite This Study

Lv et al. (2023) studied this question.

synapsesocial.com/papers/6a95c2d154cfa1bfdc09e0e1https://doi.org/10.1038/s41598-023-28351-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B2026
  2. 2Retrospective analysis of predictors for significant hepatic inflammation in metabolic-associated fatty liver disease with chronic hepatitis B2026
  3. 3[Altered oral microbiome and metabolites are associated with improved lipid metabolism in HBV-infected patients with metabolic dysfunction-associated fatty liver disease].2025 · 2 citations
  4. 4Proportion and clinical characteristics of metabolic-associated fatty liver disease and associated liver fibrosis in an urban Chinese population2024 · 6 citations
  5. 5Metabolic multimorbidity and liver fibrosis among people with hepatitis B in Senegal.2026